Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that Ultimate Sports Nutrition is designing a new product line targeting the New Zealand and Australian markets. This line of products will be formulated using company’s patented Phytofare® complex. As per the new contract, the USN can assess the applications of the Phytofare® with other contract manufacturers. The idea is to use the Plandai ingredient in supplement products in the EU and South Africa. This contract will help Plandai to extend its reach in the untapped markets.
Plandaí and its subsidiary firms formulate highly phyto-available extracts, and controls every part of the process, from cultivating the raw materials on its farms to producing Phytofare® extracts in-house, enabling the company to assure the continuity of supply and quality control throughout the process.
ENDEXX CORP (OTCMKTS:EDXC) Client Acquires Medical Marijuana License in NY
ENDEXX announced that its subsidiary firm GreenLeaf Consulting completed a bid for the firm, ‘Etain’ in New York. It is one of the five enterprises that received a license to grow and dispense medical pot in the New York. Joseph Stevens, the President of GreenLeaf expressed that they are proud of Etain as an enterprise as it is a strong group of women motivated by and committed to offering the state-of-the-art services to the patients in NY.
Gilead Sciences, Inc. (NASDAQ:GILD) Reports Results From The AMBITION Study
Gilead reported detailed report covering the findings of the AMBITION study. It is a randomized, multicenter trial of first-line combination treatment with Tadalafil and AMBrIsentan in patients suffering with pulmonary arterial hypertension. The study was conducted together with GlaxoSmithKline plc (ADR) (NYSE:GSK) and the data was released in The New England Journal of Medicine.
In last trading session, the stock price of Plandai Biotechnology gained more than 10% to close the trading session at $0.13905. The gains came at a share volume of 41,735 compared to average monthly share volume of 98,623.